What ipamorelin is

Ipamorelin is a synthetic pentapeptide, meaning it is built from five amino acids. Its full sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was developed in the late 1990s by Novo Nordisk researchers who were looking for growth hormone secretagogues with a cleaner side-effect profile than the GHRPs that had been studied previously. It was never taken to approval for any human indication.

The compound works by binding to the ghrelin receptor, formally called the growth hormone secretagogue receptor type 1a (GHSR-1a). This receptor, located on pituitary somatotroph cells and in the hypothalamus, is a separate pathway from the GHRH receptor used by compounds like sermorelin and CJC-1295. When ipamorelin binds GHSR-1a, it triggers pulsatile GH release from the pituitary. Because the ghrelin receptor is also involved in appetite regulation and other processes, how a compound interacts with it matters considerably. In the preclinical research, ipamorelin was characterized as selective: it stimulated GH release at doses that did not significantly increase cortisol, prolactin, or ACTH, a profile that distinguishes it from older GHRPs like GHRP-2 and GHRP-6.

Selectivity, in this context, is a pharmacological term describing receptor binding and downstream signaling in controlled experimental conditions. It is not a claim that the compound is free of side effects in humans, or that its effects at real-world doses and dosing frequencies match what was observed in animal research.

Regulatory status

Ipamorelin has never been FDA-approved for any human use.

Unlike sermorelin, which had a period of FDA approval for pediatric GH deficiency before being withdrawn, ipamorelin never received approval for any indication. It was studied in early-stage pharmaceutical research but did not advance through the full clinical trial and approval pathway. Today it is sold primarily as a research compound labeled "for research use only" and without a prescription requirement. Research-labeled ipamorelin is not cleared by the FDA for human use. It is not a compounded drug, and there is no approved formulation of ipamorelin in the United States. Physicians cannot legally prescribe an unapproved compound through a compounding pharmacy in the way they can with certain other peptides that had prior approvals or are on specific lists. Anyone purchasing ipamorelin as a research compound should understand the regulatory category they are operating in.

The absence of a clinical approval pathway means the gaps in the human evidence base are structural, not just a matter of time. The trials that would establish safety, efficacy, and dosing parameters in humans were not completed for ipamorelin. What exists instead is a body of preclinical data, a small number of early-stage human studies, and an extensive body of anecdotal reports from users of research compounds.

The ipamorelin and CJC-1295 pairing

Ipamorelin is discussed so frequently alongside CJC-1295 that the two compounds are often treated as a unit. Understanding the logic of that pairing, and its limits, is important for evaluating vendor claims.

CJC-1295 is a GHRH analog. It works through the GHRH receptor on pituitary cells, mimicking the hypothalamic signal to release GH. Ipamorelin works through the ghrelin receptor, a separate pathway. In theory, stimulating both pathways simultaneously could produce greater GH release than either compound alone, because the two signals arrive through different receptor systems. This is the pharmacological rationale for the pairing.

The rationale is mechanistically plausible. Combining a GHRH signal with a ghrelin-pathway signal does increase GH release in animal models more than either alone in some studies. The problem is that the specific combination of ipamorelin with CJC-1295 has not been studied in controlled human trials. The "synergy" framing that appears in vendor marketing is extrapolated from that mechanistic logic and from animal data, not demonstrated in humans at the doses and frequencies commonly sold. Informational ranges discussed in the research literature vary considerably; no approved dosing protocol exists for either compound, and none for the combination.

This is worth stating plainly: the most heavily marketed use of ipamorelin, as part of a stacked preparation with CJC-1295, is among the least studied configurations of either compound. That does not make it necessarily dangerous or ineffective. It means the evidence base does not yet support the confidence level implied by much of the marketing around it.

How ipamorelin is discussed and marketed

Online discussion of ipamorelin centers on four main areas. Here is what the research actually establishes in each one, and where the extrapolation begins.

Area 1

GH axis stimulation

The mechanism is established in preclinical research. Ipamorelin binds GHSR-1a and triggers GH pulses. Animal studies confirmed dose-dependent GH increases. Limited human data exists; the compound produced GH responses in small early-phase studies. Whether those GH changes carry meaningful clinical outcomes in healthy adults has not been established in large trials.

Limited human data
Area 2

Body composition

Vendor marketing frequently ties ipamorelin to lean mass gains and fat reduction, citing the known role of GH in body composition. The clinical evidence linking ipamorelin specifically to those outcomes in humans is not established. The reasoning is GH raises IGF-1, IGF-1 supports anabolism, therefore ipamorelin improves body composition. Each step involves extrapolation.

Preclinical / extrapolated
Area 3

Recovery and repair

GH and IGF-1 play documented roles in tissue maintenance and repair. Marketing frequently connects ipamorelin to recovery from training and connective tissue support on this basis. No ipamorelin-specific human trials on recovery outcomes exist. The connection is mechanistically plausible but not established by direct evidence in humans.

Extrapolated only
Area 4

Sleep quality

GH secretion is strongly linked to slow-wave sleep, and some research suggests ghrelin pathway activity plays a role in sleep architecture. Studies looking at ipamorelin's specific effects on sleep in humans are not available. The connection between ghrelin receptor agonism and sleep is a real area of research; clinical outcomes from ipamorelin specifically are not established.

Emerging / preliminary

The pattern across all four areas is consistent: ipamorelin has a real, pharmacologically characterized mechanism. The distance between that mechanism and demonstrated clinical outcomes in healthy adults is large, and most vendor marketing does not make that distance clear.

How to evaluate a vendor selling ipamorelin

Because ipamorelin has no approved pharmaceutical formulation, anyone purchasing it is purchasing a research compound. That category carries specific quality and compliance considerations that matter for both safety and legal reasons.

Vendor evaluation checklist

  • Third-party COA from an accredited lab: The certificate of analysis should come from a laboratory independent of the vendor, with ISO 17025 accreditation or equivalent. The lab name, accreditation number, and contact should be independently verifiable. A COA produced by the vendor's own facility offers significantly less assurance.
  • Batch traceability: The COA should reference the specific batch number on the product you are receiving. An undated or batch-unspecific COA cannot confirm what is in the vial you have. Reputable vendors make batch-specific documentation available before or at the time of purchase.
  • Purity and identity methods: Look for HPLC purity data (ideally above 98%) combined with mass spectrometry or amino acid analysis confirming the peptide's identity. Purity by a single method alone does not confirm you have the correct compound.
  • Claims scope: A vendor making treatment, outcome, or curative claims about ipamorelin is operating outside the legal scope of research compound sales. Strong efficacy claims are a compliance signal worth taking seriously.
  • Labeling clarity: Research compounds must be labeled "for research use only, not for human use." A vendor whose labeling is ambiguous about the intended use category is a vendor whose regulatory posture is unclear.
  • Business verifiability: Reputable research vendors offer visible and verifiable contact information, physical business addresses, and a clear process for batch verification or inquiry. Vendors operating without a verifiable identity present a different risk profile.

Affiliate disclosure: The link below is a paid affiliate relationship. We earn a commission if you purchase through it. This relationship did not influence our evaluation criteria or any editorial content on this page. See our full disclosure policy.

Looking for a vendor that meets these criteria?

We reviewed vendors against the checklist above. The following link goes to a vendor whose COA documentation and batch traceability we found consistent with the standards described in this article. We have not evaluated the product itself, and this is not a clinical recommendation.

View vendor COA documentation Affiliate link

Ipamorelin belongs to the GHRP class of growth hormone secretagogues. Several related compounds are frequently discussed in the same context, and understanding how their mechanisms and evidence bases differ helps clarify what any one of them can and cannot claim.

CJC-1295

A GHRH analog that binds the GHRH receptor, the pathway complementary to ipamorelin's ghrelin receptor mechanism. Engineered for extended half-life through albumin binding. Small human studies exist. Research compound only; no FDA approval.

Read CJC-1295 explainer →
Sermorelin

A GHRH analog comprising the first 29 amino acids of endogenous GHRH. The only GHRH analog with a prior FDA approval history (Geref, withdrawn 2008). Now sold compounded or as a research compound. Distinct mechanism from ipamorelin.

Read Sermorelin explainer →
Tesamorelin

The only currently FDA-approved GHRH analog in the United States (Egrifta, for HIV-associated lipodystrophy). Works through the GHRH receptor. Its approval is for a specific, narrow indication; off-label use is a separate consideration.

Read Tesamorelin explainer →

Sources

  1. 1 Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed
  2. 2 Hansen BS, Raun K, Nielsen KK, Johansen NL, Hansen TK, Peschke B, et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999;141(2):180-189. PubMed
  3. 3 Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest. 2003;26(9):799-813. PubMed
  4. 4 Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
  5. 5 Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. PubMed
  6. 6 FDA. Human drug compounding. Regulatory information on sections 503A and 503B compounding. FDA.gov
  7. 7 Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39. PubMed

Frequently asked questions

What is ipamorelin?
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release from the pituitary by binding the ghrelin receptor (GHSR-1a). It is classified as a growth hormone secretagogue and a growth hormone releasing peptide (GHRP). It was developed in the late 1990s and studied in animal models for its GH-stimulating properties. It has never received FDA approval for any human indication and is sold today as a research compound not cleared for human use.
Ipamorelin vs CJC-1295: what is the difference?
The two compounds work through different receptors. Ipamorelin is a GHRP that binds the ghrelin receptor (GHSR-1a). CJC-1295 is a GHRH analog that binds the GHRH receptor on pituitary cells. Both pathways result in GH secretion from the pituitary, but they arrive through separate receptor systems. The rationale for pairing them is that complementary stimulation through two different pathways may produce greater GH release than either alone, a hypothesis that is pharmacologically plausible and supported in some animal research. Controlled human trials evaluating the specific ipamorelin-CJC-1295 combination have not been published. Both compounds are research compounds with no active FDA approval for the uses most commonly marketed.
Is ipamorelin legal?
Ipamorelin is not a scheduled controlled substance in the United States. It is also not an FDA-approved drug. Research-labeled ipamorelin sold without a prescription occupies a legally ambiguous position: it cannot be legally sold for human consumption, but purchasing or possessing it is not the same as obtaining a controlled substance. The FDA has taken enforcement actions against vendors of peptide research compounds and has signaled interest in tightening oversight of this category. The regulatory landscape is actively evolving and varies by jurisdiction. This is not legal advice; consult a licensed attorney or healthcare provider for guidance specific to your situation.
What does the research show about ipamorelin's effects?
The strongest evidence for ipamorelin comes from preclinical animal studies, which documented GH release with a more selective side-effect profile than older GHRPs like GHRP-2 and GHRP-6. Ipamorelin produced GH pulses without significant elevations in cortisol, prolactin, or ACTH at therapeutic doses in those studies. Human data is very limited; the compound did not advance through a full clinical trial program. Most vendor marketing claims, particularly around body composition, recovery, and sleep, extrapolate from the animal data or from the broader GH literature rather than from ipamorelin-specific human trials. The gap between what the mechanism suggests and what controlled human research has established is wide.
What study ranges are discussed in the ipamorelin research?
Animal studies used a range of doses to characterize the dose-response relationship. Human reference ranges do not exist in a clinical sense because ipamorelin never completed the approval process. Published research literature has discussed doses in the range of 200 to 300 micrograms per administration in early human studies, but these were investigational contexts with defined protocols, monitoring, and endpoints. These figures are informational only and do not constitute a dosing protocol. There is no approved human protocol for ipamorelin. Anyone using or considering this compound should do so under the supervision of a licensed and informed healthcare provider.